Menarini Group engages in R&D to bridge an unmet global need for advanced research in healthcare biotechnology and diagnostics. We place strong emphasis on advancing highly specialised and scientifically valuable fields through close collaborations with academic and medical institutions to elevate the standard of healthcare not only in Asia, but globally.

While leveraging Singapore’s reputation for quality research and development (R&D) as an international biomedical hub that encompasses the entire innovation and manufacturing value chain, we also benefit from the country’s supportive operating environment and talent pool.

In 2021, Menarini Asia-Pacific, through A. Menarini Biomarkers Singapore Pte Ltd (MBS), signed a memorandum of understanding with the SingHealth Duke-NUS Maternal and Child Health Research Institute (MCHRI) to create a regional and international medical hub in Singapore for non-invasive diagnostics in prenatal, and targeted therapies for better clinical outcomes.